J F R Robertson
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson J. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol 2013; 24:2543-8.
20.06.2013Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
20.06.2013Ann Oncol 2013; 24:2543-8
Jonat W, Bachelot T, Ruhstaller Thomas, Kuss I, Reimann U, Robertson J F R
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
Thürlimann B, Robertson J, Nabholtz J, Buzdar A, Bonneterre J, Arimidex Study Group. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. European journal of cancer (Oxford, England : 1990) 2003; 39:2310-7.
01.11.2003Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
01.11.2003European journal of cancer (Oxford, England : 1990) 2003; 39:2310-7
Thürlimann Beat, Robertson J F R, Nabholtz J M, Buzdar A, Bonneterre J, Arimidex Study Group
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
Nabholtz J, Bonneterre J, Buzdar A, Robertson J, Thürlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. European journal of cancer (Oxford, England : 1990) 2003; 39:1684-9.
01.08.2003Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
01.08.2003European journal of cancer (Oxford, England : 1990) 2003; 39:1684-9
Nabholtz J M, Bonneterre J, Buzdar A, Robertson J F R, Thürlimann Beat